Pembrolizumab and Cryoablation for Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing a combination of a freezing procedure (cryoablation) and an immunotherapy drug called pembrolizumab (Keytruda) for people with triple-negative breast cancer that has spread. The goal is to see if freezing the tumor helps the immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have triple-negative breast cancer that has spread to other parts of your body.
- You have a tumor (at least 1.5 cm) in a place like the liver, lung, bone, or soft tissue that a doctor can freeze.
- Your doctor is planning to give you the immunotherapy drug pembrolizumab (Keytruda) as part of your standard treatment.
- You are able to undergo the freezing procedure safely.
- If you could become pregnant, you agree to use effective birth control during treatment and for 4 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining a freezing procedure (cryoablation) with an immune-related treatment can control triple-negative breast cancer in the breast. It may help some people by boosting the immune system to better fight the cancer.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial studies if freezing the main breast tumor (cryoablation) can help people with metastatic breast cancer who are already on treatment. It is for women whose cancer is stable or responding to treatment elsewhere in the body, but the breast tumor might still be growing.
This trial tests a new combination treatment for metastatic triple-negative breast cancer, using radiation to stimulate the immune system, an immunotherapy drug (pembrolizumab), and a medication that targets immune-suppressing cells. The goal is to boost the body's response to immunotherapy, especially in people who have already received immunotherapy but saw limited benefit.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial tests cryoablation (freezing the tumor with a needle) as a way to treat small, low-risk breast cancers without surgery. It is for women 50 or older whose cancers are hormone-receptor-positive and haven't spread to lymph nodes.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.